We dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed...

Multiple myeloma (MM) is the second most common hematologic malignancy in the world and accounts for 15% of primary hemocytopathies, with an ever...

Measures of muscle and adipose tissue mass have been associated with outcomes in several malignancies, but studies in multiple myeloma (MM) are...

Frailty assessments may help to identify patients at highest risk for treatment-related toxicity, early treatment discontinuation due to toxicity, and...

“Continuiamo a esplorare” per contribuire in modo significativo a migliorare la diagnosi, l’assistenza, il trattamento e la qualità della vita delle...

Multiple myeloma (MM) is characterized by excessive production of monoclonal immunoglobulins (M proteins).

Geriatric assessment (GA)-guided supportive care programs have been successful in improving treatment outcomes for older adults with solid-organ...

Multiple myeloma (MM) is characterized by the clonal expansion of plasma cells and the excretion of a monoclonal immunoglobulin (M-protein), or...

Acquired factor FXIII (FXIII) deficiency can be immune- or non-immune mediated and may cause severe bleeding symptoms. The incidence of acquired FXIII...

Multiple myeloma (MM) is a heterogeneous neoplasm accounting for the second most prevalent hematologic disorder.